PMID- 18451512
OWN - NLM
STAT- MEDLINE
DCOM- 20080619
LR  - 20221207
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 31
IP  - 5
DP  - 2008 May
TI  - Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates the 
      development of dermatitis and inhibits immunoglobulin E production in atopic 
      dermatitis model NC/Nga mice.
PG  - 884-9
AB  - We have previously shown that the oral administration of heat-killed 
      Lactobacillus brevis (L. brevis) SBC8803 strain inhibits IgE production in 
      ovalbumin (OVA)-sensitized BALB/c mice through improvement of the type-1 helper T 
      (Th1)/Th2 balance toward Th1 dominance. Atopic dermatitis is one of the most 
      common skin diseases and is frequently associated with elevated immunoglobulin E 
      (IgE) antibodies against many kinds of allergens. In this study, we investigated 
      the inhibitory effect of oral administration of L. brevis SBC8803 on the 
      development of dermatitis and IgE elevation using the NC/Nga atopic dermatitis 
      model mice. Male 8-week-old NC/Nga mice were sensitized by the topical 
      application of picryl chloride to foot pads and shaved abdomen. These mice were 
      boosted with picryl chloride by topical application onto the ears once a week for 
      9 weeks. The mice (n=10 per group) were fed a diet containing 0%, 0.05% or 0.5% 
      of heat-killed L. brevis SBC8803 from 2 weeks before the first sensitization to 
      the end of the study. Total IgE concentration in serum, clinical score, and ear 
      thickness were periodically examined throughout the study. Finally, cytokine 
      (interleukin (IL)-4, IL-5, IL-6, IL-10, IL-12, IFN-gamma and transforming growth 
      factor (TGF)-beta) productions from splenocytes and Peyer's patch (PP) cells of 
      mice were measured. Oral administration of L. brevis SBC8803 significantly 
      inhibited IgE production and ear swelling, and suppressed the development of 
      dermatitis in a dose-dependent manner. Immunosuppressive cytokines such as IL-10 
      and TGF-beta production from PP cells significantly increased in the 0.5% group 
      compared to the control group although Th1-type and Th2-type cytokines production 
      was not affected.
FAU - Segawa, Shuichi
AU  - Segawa S
AD  - Frontier Laboratories of Value Creation, Sapporo Breweries Ltd, 10 Okatohme, 
      Yaizu, Shizuoka 425-0013, Japan. syuuichi.segawa@sapporobeer.co.jp
FAU - Hayashi, Atsushi
AU  - Hayashi A
FAU - Nakakita, Yasukazu
AU  - Nakakita Y
FAU - Kaneda, Hirotaka
AU  - Kaneda H
FAU - Watari, Junji
AU  - Watari J
FAU - Yasui, Hisako
AU  - Yasui H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukins)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Dermatitis, Atopic/*prevention & control
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Immunoglobulin E/*biosynthesis
MH  - Immunosuppressive Agents/administration & dosage/chemistry/*pharmacology
MH  - Interleukins/biosynthesis
MH  - Levilactobacillus brevis/*chemistry
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Peyer's Patches/cytology/drug effects/metabolism
MH  - Skin/pathology
MH  - Spleen/cytology/drug effects/metabolism
MH  - Th1 Cells/drug effects/immunology/metabolism
MH  - Th2 Cells/drug effects/immunology/metabolism
MH  - Transforming Growth Factor beta1/biosynthesis
EDAT- 2008/05/03 09:00
MHDA- 2008/06/20 09:00
CRDT- 2008/05/03 09:00
PHST- 2008/05/03 09:00 [pubmed]
PHST- 2008/06/20 09:00 [medline]
PHST- 2008/05/03 09:00 [entrez]
AID - JST.JSTAGE/bpb/31.884 [pii]
AID - 10.1248/bpb.31.884 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2008 May;31(5):884-9. doi: 10.1248/bpb.31.884.